GNMX Aevi Genomic Medicine Inc.

0.19
0  2%
Previous Close 0.18
Open 0.18
Price To Book 18.83
Market Cap 12,195,604
Shares 64,766,882
Volume 67,050
Short Ratio
Av. Daily Volume 2,038,496

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released January 2, 2019 did not meet primary endpoint.
AEVI-001 (NFC-1)
ADHD
Phase 1b initial data due 2H 2019.
AEVI-002 (Anti-LIGHT mAb)
Pediatric onset Crohn's disease
Phase 1/2 commencement of enrollment announced January 31, 2017.
AEVI-001 (NFC-1)
22q11.2 Deletion Syndrome
Phase 2/3 data released March 20, 2017 - primary endpoint not met. Subset of data released April 20, 2017 - to be presented April 21, 2017.
NFC-1 - SAGA
mGluR mutation positive ADHD